QuantLogix ← BSX scorecard
📅 BSX Earnings Preview
Boston Scientific Corp.
Next report (est.)
11/25/2026
Countdown
75 days
EPS growth YoY
+15.1%
Revenue growth YoY
+7.5%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/03/2026 ±5.2% +3.6% over-priced
05/01/2026 ±4.4% -1.9% over-priced
11/03/2025 ±1.7% -2.1% under-priced
08/01/2025 ±1.5% +0.5% over-priced
05/01/2025 ±1.7% +0.3% over-priced
11/01/2024 ±2.3% -0.5% over-priced
08/01/2024 ±2.9% +1.7% over-priced
05/01/2024 ±2.7% +0.5% over-priced
Across these reports, options implied an average ±2.8% move vs an actual average of 1.4% — the stock stayed inside the implied band 88% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $0.61 $5.4B $905M
Q1 FY2026 $0.90 $5.2B $1.3B
Q4 FY2025 $0.45 $5.3B $670M
Q3 FY2025 $0.51 $5.1B $755M
Analyst posture
Buy / Strong Buy
30
Hold
8
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Underweight · 22/100 Full scorecard →
Get alerted before every BSX report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on BSX before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Boston Scientific Corp. (BSX) reports in 75 days, with the next report estimated for 11/25/2026. Across the last 8 reports, options priced an average ±2.8% earnings move while the stock actually moved 1.4% on average — the market has systematically over-priced BSX's earnings risk. Fundamentals into the print: EPS up 15.1% year-over-year, revenue up 7.5%. QuantLogix's live 5-factor engine currently reads BSX as a underweight at 22/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →